ACAD Earnings Preview: Options Price a ±8.6% Move

· The NYC Memo · ACAD reports 2026-11-04

ACADIA Pharmaceuticals Inc. reports November 4, 2026. The November 20, 2026 straddle implies ±8.60% against a 5.28% average reaction, with dealers long gamma and max pain at $20.

Live updates

Nov 4 — Ahead of ACAD earnings on November 4, 2026, the implied move contracted from ±9.23% to ±8.60% as at-the-money implied volatility fell from 55.4% to 47.6%, reflecting lower market expectations for post-announcement share price volatility.

Nov 3 — Ahead of earnings on November 4, 2026, the implied move for ACAD widened from plus or minus 8.89 percent to plus or minus 9.23 percent, implying that options traders anticipate a larger post-event price reaction.

ACADIA Pharmaceuticals Inc. reports Q3 2026 earnings on November 4, 2026, after close, with spot at $20.57. For the November 20, 2026 expiry, the options market prices a $1.77 straddle, implying an 8.60% move and a range of $18.80 to $22.34 at an ATM IV of 47.6%. This expected swing exceeds the average realised reaction of 5.28% across 8 prints counted, where shares finished higher 6 times and lower 2 times.

Consensus calls for an EPS estimate of $0.20 on a revenue estimate of $0.3bn. Dealers maintain a long gamma lean, which should suppress volatility and anchor trading near the $20 max pain level. The put/call OI stands at 0.74.

What the market will be watching

Acadia Pharmaceuticals will hinge on prescription demand and patient persistence trends across its commercial treatments. The desk will focus on commercial momentum in Rett syndrome and Parkinson's disease psychosis therapies, watching for signs of flattening adoption. Margin performance faces pressure from expanding research costs and commercial spending. Options traders will react primarily to changes in full-year guidance and shifts in payer coverage dynamics. Pipeline progress on late-stage clinical programs will dictate post-earnings volatility and positioning.

What the options market is pricing

MeasureLevel
PrintNovember 4, 2026, After Close
Expiry usedNovember 20, 2026 (16 days out)
Spot$20.57
ATM straddle$1.77
Implied move±8.60% ($18.80 to $22.34)
ATM implied vol47.6%
Put/call open interest0.74
Max pain$20
Net dealer gamma+$0.43mn per 1% move, LONG GAMMA
Heaviest call strike above spot$21 (7,037 contracts)
Heaviest put strike below spot$20 (4,293 contracts)
Street EPS estimate$0.20
Street revenue estimate$0.34bn

Dealers sit long gamma into the print, which means their hedging leans against the move and tends to compress ACAD between catalysts. That damping disappears the moment the number crosses the tape.

How the stock has reacted before

ReportNext-day move
Q2 2026, Aug 4+6.08%
Q1 2026, May 6+5.03%
Q4 2025, Jan 13-0.49%
Q3 2025, Nov 5-3.05%
Q2 2025, Aug 6+2.52%
Q1 2025, May 7+14.31%
Q4 2024, Feb 26+1.79%
Q3 2024, Nov 6+8.93%

Across the last 8 prints the average absolute reaction is 5.28%, with 6 higher and 2 lower. The best was +14.31% and the worst -3.05%. Options are asking ±8.60%, which is 3.32 points richer than the realised average, the premium seller's case.

Where the stock is trading

MeasureLevel
Spot$20.57
52-week range$18.39 to $30.96
Position in that range17%
From the 52-week high-33.6%
From the 52-week low+11.8%
Past week+2.0%
Past month+2.3%
Past three months-28.6%
50-day average$23.38
200-day average$23.62

How the options market is pricing it

The November 20, 2026 straddle marks $18.80 to $22.34 as the range the options market is paying for into the print, with ATM implied vol at 48% set to drain the morning after. A reaction inside that band hands the edge to premium sellers; a break outside it rewards premium buyers. Historically ACAD has moved 5.28% on earnings against the ±8.60% now implied, so the market is pricing this print richer than the recent average. Which side of that trade is right depends on the number, the guidance and where positioning unwinds.

Read the mechanics behind the crush in our earnings volatility guide, and pull the live memo for ACAD before the print.

Data as of November 4, 2026 from the live option chain, exchange price history and SEC-dated earnings reactions. This is research, not investment advice.

Related: ACAD options memo

More earnings previews